Antibodies induced by the HA2 glycopolypeptide of influenza haemagglutinin improve recovery from influenza A virus infection

Journal of General Virology

Volumn 89, Issue 4, 2008, Pages 958-967

  Gocnik M ^a   Fislova T ^a   Mucha, V ^a   Sladkova T ^a   Russ, G ^a   Kostolansky F ^a   Vareckova E ^a  

^a INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPOLYPEPTIDE HA1; GLYCOPOLYPEPTIDE HA2; IMMUNOGLOBULIN G; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; KG 11; KG 12; KG12; VIRUS ANTIBODY; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHIMERA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MALE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROVOCATION TEST; SURVIVAL RATE; VACCINIA VIRUS; VIRUS HEMAGGLUTINATION; VIRUS RECOMBINATION; VIRUS STRAIN; ANIMAL; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; BLOOD; GENETIC REASSORTMENT; GENETICS; IMMUNIZATION; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORTHOMYXOVIRUS INFECTION; PROTEIN ENGINEERING; VACCINIA;

INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE; VACCINIA VIRUS;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNIZATION; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN ENGINEERING; REASSORTANT VIRUSES; VACCINES, SYNTHETIC; VACCINIA;

EID: 45549102325     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.83524-0     Document Type: Article

References (30)

1. Becht H., Huang, R. T. C., Fleischer, B., Boscheck, C. B. & Rott, R. (1984). Immunogenic properties of the small chain HA2 of influenza viruses. J Gen Virol 65, 173-183.
2. Bennink, J. R., Yewdell, J. W., Smith, G. L., Moller, C. & Moss, B. (1984). Recombinant vaccinia virus primes and stimulates influenza-specific cytotoxic T cells. Nature 311, 578-579.
3. Cox, N. J., Tamblyn, S. E. & Tam, T. (2003). Influenza pandemic planning. Vaccine 21, 1801-1803.
4. Fislová, T., Sladková, T., Gocník, M., Mucha, V., Varečková, E. & Kostolanský, F. (2005). Differences in antibody responses of mice to intranasal or intraperitoneal immunization with influenza A virus and vaccination with subunit influenza vaccine. Acta Virol 49, 243-250.
5. Gerhard, W. (2001). The role of the antibody response in influenza virus infection. Curr Top Microbiol Immunol 260, 171-190.
6. Gerhard, W., Mozdzanowska, K. & Zharikova, D. (2006). Prospects for universal influenza virus vaccine. Emerg Infect Dis 12, 569-574.
7. Gocnik, M., Fislová, T., Sládková, T., Mucha, V., Kostolanský, F. & Varečková, E. (2007). Antibodies specific to the HA2 glycopolypeptide of influenza A virus with fusion-inhibition activity contribute to the protection of mice against lethal infection. J Gen Virol 88, 951-955.
8. Gould, K. G., Scotney, H., Townsend, A. R., Bastin, J. & Brownlee, G. G. (1987). Mouse H-2k-restricted cytotoxic T cells recognize antigenic determinants in both the HA1 and HA2 subunits of the influenza A/PR/8/34 hemagglutinin. J Exp Med 166, 693-701.
9. Kostolanský, F., Mucha, V., Slováková, R. & Varečková, E. (2002). Natural influenza A virus infection of mice elicits strong antibody response to HA2 glycopolypeptide. Acta Virol 46, 229-236.
10. Lipatov, A. S., Govorkova, E. A., Webby, R. J., Ozaki, H., Peiris, M., Guan, Y., Poon, L. & Webster, R. G. (2004). Influenza: emergence and control. J Virol 78, 8951-8959.
11. Luke, C. J. & Subbarao, K. (2006). Vaccines for pandemic influenza. Emerg Infect Dis 12, 66-72.
12. Moss, B. (1996). Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A 93, 11341-11348.
13. Mozdzanowska, K., Feng, J., Eid, M., Kragol, G., Cudic, M., Otvos, L. & Gerhard, W. (2003). Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21, 2616-2626.
14. Neirynck, S., Deroo, T., Saelens, X., Vanlandschoot, P., Jou, W. M. & Fiers, W. (1999). A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5, 1157-1163.
15. Nobusawa, E., Aoyama, T., Kato, H., Suzuki, Y., Tateno, Y. & Nakajima, K. (1991). Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses. Virology 182, 475-485.
16. Palladino, G., Mozdzanowska, K., Washko, G. & Gerhard, W. (1995). Virus-neutralizing antibodies of immunoglobulin G (IgG) but not IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol 69, 2075-2081.
17. Russ, G., Varečková, E. & Styk, B. (1974). Steric effects in the reaction of influenza virus neuraminidase with antibodies. Acta Virol 18, 299-306.
18. Russ, G., Poláková, K., Kostolanský, F., Styk, B. & Vančiková, M. (1987). Monoclonal antibodies to glycopeptides HA1 and HA2 of influenza virus hemagglutinin. Acta Virol 31, 374-386.
19. Saikh, K. U., Martin, J. D., Nishikawa, A. H. & Dillon, S. B. (1995). Influenza A virus-specific H-2d restricted cross-reactive cytotoxic T lymphocyte epitope(s) detected in the hemagglutinin HA2 subunit of A/Udorn/72. Virology 214, 445-452.
20. Sánchez-Fauquier, A., Villanueva, N. & Melero, J. A. (1987). Isolation of cross-reactive, subtype-specific monoclonal antibodies against influenza virus HA1 and HA2 hemagglutinin subunits. Arch Virol 97, 251-265.
21. Stephenson, I., Nicholson, K. G., Wood, J. M., Zambon, M. C. & Katz, J. M. (2004). Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 4, 499-509.
22. Styk, B., Russ, G. & Poláková, K. (1979). Antigenic glycopolypeptides HA1 and HA2 of influenza virus hemagglutinin. III. Reactivity with human convalescent sera. Acta Virol 23, 1-8.
23. Tamura, S., Tanimoto, T. & Kurat, T. (2005). Mechanism of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 58, 195-207.
24. Tkáčová, M., Varečková, E. Baker, I. C., Love, J. M. & Ziegler, T. (1997). Evaluation of monoclonal antibodies for subtyping of currently circulating human type A influenza viruses. J Clin Microbiol 35, 1196-1198.
25. Varečková, E., Betáková, T., Mucha, V., Soláriková, L., Kostolanský, F., Waris, M. & Russ, G. (1995). Preparation of monoclonal antibodies for the diagnosis of influenza A infection using different immunization protocols. J Immunol Methods 180, 107-116.
26. Varečková, E., Cox, N. & Klimov, A. (2002). Evaluation of subtype specificity of monoclonal antibodies raised against H1 and H3 subtypes of human influenza A virus hemagglutinins. J Clin Microbiol 40, 2220-2223.
27. Varečková, E., Mucha, V., Wharton, S. A. & Kostolanský, F. (2003a). Inhibition of fusion activity of influenza A mediated by HA2-specific monoclonal antibodies. Arch Virol 148, 469-486.
28. Varečková, E., Wharton, S. A., Mucha, V., Gocník, M. & Kostolanský, F. (2003b). A monoclonal antibody specific to the HA2 glycoprotein of influenza A hemagglutinin that inhibits its fusion activity reduces replication of the virus. Acta Virol 47, 229-236.
29. Varečková, E., Blaškovičová, H., Gocník, M., Mikas, J., Adamčáková, J., Fislová, T., Kostolanský, F. & Mucha, V. (2006). Evaluation of clinical specimens for influenza A virus positivity using various diagnostic methods. Acta Virol 50, 181-186.
30. WHO (2006). Recommendation for Influenza Vaccine Composition. Northern Hemisphere: 2006-2007. http://www.who.int/csr/disease/ influenza/vaccinerecommendations1/en/index.html